Geron (GERN) is anticipated to report a quarterly loss of $0.03 per share and revenues of $52.49 million for the quarter ending September 2025, reflecting substantial year-over-year growth. However, recent analyst sentiment indicates potential headwinds, with the consensus EPS estimate revised 7.69% lower over the last 30 days, and the company currently holds a negative Zacks Earnings ESP of -32.35% and a Zacks Rank #4 (Sell). This combination suggests Geron is not a strong candidate to beat consensus EPS estimates in its upcoming November 5 release, despite having exceeded expectations in three of the past four quarters.
Geron (GERN) is projected to report a quarterly loss of $0.03 per share for the September 2025 quarter, representing a 25% improvement year-over-year. Concurrently, revenues are anticipated to reach $52.49 million, marking a significant 85.7% increase from the prior-year period. These figures suggest strong top-line growth despite continued unprofitability, which is common for a biotech firm. Despite the revenue growth, analyst sentiment has turned cautious, with the consensus EPS estimate revised 7.69% lower over the last 30 days. The company's Most Accurate Estimate is now lower than the Zacks Consensus Estimate, resulting in a negative Earnings ESP of -32.35%. This, combined with a Zacks Rank #4 (Sell), indicates a low probability of Geron beating its upcoming earnings per share estimate. Historically, Geron has demonstrated a tendency to surprise positively, beating consensus EPS estimates in three of the last four quarters, including a 33.33% beat in the most recent reported quarter. However, the current negative Earnings ESP and Zacks Rank #4 strongly suggest that this historical trend may not hold for the upcoming November 5 release. The overall sentiment is moderately negative (-0.45) with a cautious tone.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
